
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

November 5, 2001

TO: Examiner Karen Canella
Group 1642
(703) 308-8362

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX RECEIVED

NOV 05 2001

GROUP 1600

FAX NO: (703) 308-4242

OF PAGES (incl. cover): 8

Re: U.S. Serial No. 09/778,963, filed February 8, 2001
Entitled "ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND
USES THEREOF"

A Preliminary Amendment (Restriction Election) and a Statement Regarding Duty of
Disclosure in the above-identified application follows. No fee is due for this filing.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

Elect / Amended B / #8
J 11/6/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: NEELAM et al.

Art Unit: 1642

Serial No.: 09/778,963

Examiner: K. Cancelli

Filed: February 8, 2001

Atty. Docket: CL001112

For: ISOLATED HUMAN RAS-LIKE
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This is in response to an Office communication mailed October 30, 2001 in which a restriction requirement was issued for the above referenced application.

By way of response, Applicants hereby elect claim group III, claims 4-6, 8-11, and 22-23, directed to nucleic acid molecules, vectors, host cells, etc., for examination and have canceled claims corresponding to the non-elected groups I-II, IV-V, and VII.

However, applicants respectfully request that the Examiner reconsider the claim division and include claim 13 in the elected group. Specifically, the point of novelty of claim 13 is the nucleic acid molecules of the claim from which it depends, claim 5. The dependent claim 13 provides a specific use (method of detecting a nucleic acid of claim 5) of the subject matter and it is believed that examination of this claim would not unduly burden the Examiner with additional review issues.